“Soft Tissue Sarcoma Pipeline Insight, 2026“ report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Soft Tissue Sarcoma Market.
The Soft Tissue Sarcoma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Soft Tissue Sarcoma Pipeline Report:
Companies across the globe are diligently working toward developing novel Soft Tissue Sarcoma treatment therapies with a considerable amount of success over the years.
Soft Tissue Sarcoma companies working in the treatment market are Eli Lilly, Philogen, Intensity Therapeutics, Peel Therapeutics, Pure Biologics, Edgewood Oncology, Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., and others, are developing therapies for the Soft Tissue Sarcoma treatment
Emerging Soft Tissue Sarcoma therapies in the different phases of clinical trials are- TAZVERIK (tazemetostat), AYVAKIT (avapritinib), LARTRUVO (olaratumab), Fibromun (L19TNF), INT230-6, PEEL-224, Selpercatinib, PBA-0405, BTX-A51, Liposomal Annamycin, and others are expected to have a significant impact on the Soft Tissue Sarcoma market in the coming years.
In May 2025, The FDA has awarded orphan drug designation (ODD) to THE001 (DPPG2-TSL-DOX), a thermosensitive liposomal doxorubicin formulation, for the treatment of soft tissue sarcoma (STS), as announced by its developer, Thermosome. This U.S. designation follows a similar orphan drug status previously granted by the European Medicines Agency for THE001 in STS patients.
In November 2025, Nivolumab (Opdivo), used alone or in combination with relatlimab (Opdualag), outperformed historical standards in treating patients with tertiary lymphoid structure (TLS)–positive soft tissue sarcoma, based on results from the phase 2 CONGRATS trial (NCT04095208).
In October 2025, The U.S. FDA granted Fast Track designation to ADCE-D01 for treating soft tissue sarcoma, according to a statement from Adcendo ApS. Dr. Victoria Marsh, the company’s Global Head of Regulatory, noted that this designation will enable more frequent communication with the FDA, helping accelerate the regulatory review process and potentially bringing ADCE-D01 to patients sooner.
In August 2025, Data from a Phase 3 study (NCT05121350) presented at the 2025 ASCO Annual Meeting showed that anlotinib combined with epirubicin provided significant efficacy advantages over epirubicin alone in patients with advanced soft tissue sarcoma.
In June 2025, According to results from stage 1 of the Phase 2a QB46C-H07 trial (NCT05755113), eight out of ten evaluable patients with soft tissue sarcoma treated with tigilanol tiglate (Stelfonta) experienced either complete or partial ablation of their tumors or tumor segments at any point during the study.
In May 2025, The FDA has granted orphan drug designation (ODD) to THE001 (DPPG2-TSL-DOX), a thermosensitive liposomal formulation of doxorubicin, for treating patients with soft tissue sarcoma (STS), according to Thermosome. This follows a prior orphan drug designation by the European Medicines Agency and results from a Phase 1 trial (NCT05858710) presented at the CTOS Annual Meeting.
In January 2025, Sonnet BioTherapeutics Holdings, Inc. (NASDAQ: SONN), a clinical-stage company specializing in targeted immunotherapeutic drugs, has announced an expansion of its Phase 1 SB101 clinical trial for SON-1010 (IL12-FHAB) in adults with advanced solid tumors. Following the successful completion of monotherapy dose escalation, the study will now include a new cohort to assess SON-1010 in combination with trabectedin (Yondelis®). This expansion aims to evaluate the immune-oncology effects of SON-1010 at the maximum tolerated dose (MTD) of 1200 ng/kg alongside trabectedin, a chemotherapy drug approved for certain advanced soft-tissue sarcomas (STS), with the goal of enhancing local immune response in the tumor microenvironment (TME).
Soft Tissue Sarcoma Overview
Soft Tissue Sarcoma is a rare type of cancer that begins in the soft tissues of the body, such as muscles, fat, blood vessels, nerves, tendons, and connective tissues. It can occur anywhere in the body but is most commonly found in the arms, legs, or abdomen. These tumors can be aggressive and may spread to other parts of the body. Early symptoms include a painless lump or swelling. Treatment options typically include surgery, radiation therapy, and chemotherapy, depending on the tumor’s size, location, and stage.
Get a Free Sample PDF Report to know more about Soft Tissue Sarcoma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/soft-tissue-sarcoma-pipeline-insight
Emerging Soft Tissue Sarcoma Drugs Under Different Phases of Clinical Development Include:
OTSA101-DTPA111In: OncoTherapy Science, Inc.
FHD-609: Foghorn Therapeutics Inc.
CFT8634: C4 Therapeutics, Inc
LVGN6051 + Anlotinib: Lyvgen Biopharma Holdings Limited
Chiauranib: Chipscreen Biosciences, Ltd.
MNPR 201: Monopar Therapeutics
AL3818: Advenchen Laboratories, LLC
Fibronum + Doxorubicin: Philogen S.p.A.
GPX-150: Monopar Therapeutics
LTX-315: Lytix Biopharma
Lurbinectedin: Jazz Pharmaceuticals
Soft Tissue Sarcoma Route of Administration
Soft Tissue Sarcoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
Oral
Parenteral
Intravenous
Subcutaneous
Topical
Soft Tissue Sarcoma Molecule Type
Soft Tissue Sarcoma Products have been categorized under various Molecule types, such as
Monoclonal Antibody
Peptides
Polymer
Small molecule
Gene therapy
Soft Tissue Sarcoma Pipeline Therapeutics Assessment
Soft Tissue Sarcoma Assessment by Product Type
Soft Tissue Sarcoma By Stage and Product Type
Soft Tissue Sarcoma Assessment by Route of Administration
Soft Tissue Sarcoma By Stage and Route of Administration
Soft Tissue Sarcoma Assessment by Molecule Type
Soft Tissue Sarcoma by Stage and Molecule Type
DelveInsight’s Soft Tissue Sarcoma Report covers around 75+ products under different phases of clinical development like
Late-stage products (Phase III)
Mid-stage products (Phase II)
Early-stage product (Phase I)
Pre-clinical and Discovery stage candidates
Discontinued & Inactive candidates
Route of Administration
Further Soft Tissue Sarcoma product details are provided in the report. Download the Soft Tissue Sarcoma pipeline report to learn more about the emerging Soft Tissue Sarcoma therapies
Some of the key companies in the Soft Tissue Sarcoma Therapeutics Market include:
Key companies developing therapies for Soft Tissue Sarcoma are – AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., Noxopharm Limited, and others.
Soft Tissue Sarcoma Pipeline Analysis:
The Soft Tissue Sarcoma pipeline report provides insights into
The report provides detailed insights about companies that are developing therapies for the treatment of Soft Tissue Sarcoma with aggregate therapies developed by each company for the same.
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Soft Tissue Sarcoma Treatment.
Soft Tissue Sarcoma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
Soft Tissue Sarcoma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Soft Tissue Sarcoma market.
The report is built using data and information traced from the researcher’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Soft Tissue Sarcoma drugs and therapies
Soft Tissue Sarcoma Pipeline Market Drivers
Increase in Cancer Cases, rising Involvement of Clinical Trials are some of the important factors that are fueling the Soft Tissue Sarcoma Market.
Soft Tissue Sarcoma Pipeline Market Barriers
However, side-Effects of Soft Tissue Sarcoma Drugs, increasing Cost of Treatments and other factors are creating obstacles in the Soft Tissue Sarcoma Market growth.
Scope of Soft Tissue Sarcoma Pipeline Drug Insight
Coverage: Global
Key Soft Tissue Sarcoma Companies: Eli Lilly, Philogen, Intensity Therapeutics, Peel Therapeutics, Pure Biologics, Edgewood Oncology, Advenchen Laboratories, Philogen, Gradalis, Epizyme, Chugai Pharma France, CytRx, Taiho Pharmaceuticals, KaryoPharm Therapeutics, Nanobiotix, Apexigen, Lytix Biopharma, Incyte Corporation, Iovance Biotherapeutics, Aadi Bioscience, Inc., AVEO Pharmaceuticals, Bayer, VasGene Therapeutics, Mirati Therapeutics, Novartis Pharmaceuticals, Incyte Corporation, Tracon Pharmaceuticals, Jiangsu Hengrui Medicine, Exelixis, Qbiotics, AstraZeneca, Loxo Oncology, ImmunityBio, Monopar Therapeutics, Chipscreen Biosciences, Ltd., Agenus, C4 Therapeutics, Inc., and others
Key Soft Tissue Sarcoma Therapies: TAZVERIK (tazemetostat), AYVAKIT (avapritinib), LARTRUVO (olaratumab), Fibromun (L19TNF), INT230-6, PEEL-224, Selpercatinib, PBA-0405, BTX-A51, Liposomal Annamycin, and others
Soft Tissue Sarcoma Therapeutic Assessment: Soft Tissue Sarcoma current marketed and Soft Tissue Sarcoma emerging therapies
Soft Tissue Sarcoma Market Dynamics: Soft Tissue Sarcoma market drivers and Soft Tissue Sarcoma market barriers
Request for Sample PDF Report for Soft Tissue Sarcoma Pipeline Assessment and clinical trials
Table of Contents
1. Soft Tissue Sarcoma Report Introduction
2. Soft Tissue Sarcoma Executive Summary
3. Soft Tissue Sarcoma Overview
4. Soft Tissue Sarcoma- Analytical Perspective In-depth Commercial Assessment
5. Soft Tissue Sarcoma Pipeline Therapeutics
6. Soft Tissue Sarcoma Late Stage Products (Phase II/III)
7. Soft Tissue Sarcoma Mid Stage Products (Phase II)
8. Soft Tissue Sarcoma Early Stage Products (Phase I)
9. Soft Tissue Sarcoma Preclinical Stage Products
10. Soft Tissue Sarcoma Therapeutics Assessment
11. Soft Tissue Sarcoma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Soft Tissue Sarcoma Key Companies
14. Soft Tissue Sarcoma Key Products
15. Soft Tissue Sarcoma Unmet Needs
16 . Soft Tissue Sarcoma Market Drivers and Barriers
17. Soft Tissue Sarcoma Future Perspectives and Conclusion
18. Soft Tissue Sarcoma Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
